Genevieve Marie Boland

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kenneth K. Tanabe · 2 shared papers, 2024–2026 · strength 0.54
   • Paper The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. DOI 10.1016/j.isci.2026.116500↗
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
2. Ibrahim Ragab Eissa · 1 shared paper, 2026 · strength 0.39
   • Paper The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. DOI 10.1016/j.isci.2026.116500↗
3. Anastasios Karneris · 1 shared paper, 2024 · strength 0.36
   • Paper Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Duc… DOI 10.1245/s10434-023-14395-2↗
4. David Tsai Ting · 2 shared papers, 2024 · strength 0.29
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
   • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
5. Theodore Sunki Hong · 1 shared paper, 2024 · strength 0.15
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
6. Carlos Fernández-del Castillo · 1 shared paper, 2024 · strength 0.15
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
7. Michael D. Lanuti · 1 shared paper, 2024 · strength 0.15
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
8. Onofrio A. Catalano · 1 shared paper, 2024 · strength 0.15
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
9. Peter D. Caravan · 1 shared paper, 2024 · strength 0.15
   • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
10. Shadi Abdar Esfahani · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
11. Hua Ma · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
12. Hannah Johnson Roberts · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
13. Motaz Qadan · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
14. Aparna R. Parikh · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
15. Colin D. Weekes · 1 shared paper, 2024 · strength 0.15
    • Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
16. Marc Wehrli · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
17. Samantha R. Guinn · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
18. Marcela Valderrama Maus · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
19. Diego Salas‐Benito · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
20. Richard Andrew Burkhart · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
21. Elizabeth M. Jaffee · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
22. Andrew Scott Liss · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
23. Lei Zheng · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗
24. Jacquelyn W. Zimmerman · 1 shared paper, 2024 · strength 0.14
    • Paper Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Strom… DOI 10.1158/1078-0432.ccr-23-3841↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.